Molecular Partners AG (XSWX:MOLN)
CHF 3.395 0.09 (2.72%) Market Cap: 111.59 Mil Enterprise Value: -59.19 Mil PE Ratio: 0 PB Ratio: 0.66 GF Score: 53/100

Molecular Partners AG Corporate Call Transcript

Jan 10, 2022 / 12:00PM GMT
Release Date Price: CHF18.66 (+22.76%)
Operator

Good day, and welcome to the EMPATHY Part A Top Line Results Call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to Seth Lewis, Senior Vice President, Investor Relations. You may begin.

Seth D. Lewis
Molecular Partners AG - SVP of IR, Communications & Strategy

Thank you, Michelle. Good morning. And welcome to this conference call to review the positive top line data from Part A of the EMPATHY study, a global trial of ensovibep, a DARPin antiviral therapeutic for COVID-19.

My name is Seth Lewis, Senior Vice President of Investor Relations at Molecular Partners. And I'm joined this morning by Patrick Amstutz, Chief Executive Officer; [Chief] Officer; Michael Stumpp; Chief Operating Officer; and Nicolas Leupin. (technical difficulty) opening remarks.

And before we begin today's call, I'd like to remind, I'm making certain forward-looking statements and that these may be subject to change (technical difficulty) a public filing. (inaudible) to this on replay, this call was recorded

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot